A single protein may be holding back CAR T cancer therapy

A newly identified protein called NFIL3 is found to cause CAR T-cell therapy to lose effectiveness over time by inducing exhaustion in engineered immune cells. Disabling NFIL3 in animal models improved the cells' strength and tumor control.